Pharmaceuticals: suspected anti-competitive agreements

The CMA is investigating alleged anti-competitive agreements in the pharmaceutical sector under Chapter I CA98 and Article 101 TFEU (case reference: 50511-2).

Case timetable

Date Action
Q1 2019 (estimate) Decision on whether to issue a statement of objections for certain alleged anti-competitive agreements and/or concerted practices and certain parties
July 2018 to Q1 2019 Further investigation including further information gathering in relation to certain alleged anti-competitive agreements and/or concerted practices and certain parties. CMA analysis and review of information gathered
October 2017 to June 2018 Initial investigation and information gathering. CMA analysis and review of information gathered
October 2017 Investigation opened

Case information

On 10 October 2017, the CMA launched an investigation under Chapter 1 of the CA98 and Article 101 of the TFEU into suspected breaches of competition law by various parties. The investigation relates to alleged anti-competitive agreements and/or concerted practices in relation to generic pharmaceutical products.

The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.

Contacts

Assistant Project Director

Nicholas Scola (020 3738 6931, nicholas.scola@cma.gov.uk)

Project Director

Geoff Steadman (020 3738 6311, geoff.steadman@cma.gov.uk)

Senior Responsible Officer

Ann Pope (020 3738 6786, ann.pope@cma.gov.uk)

Published 12 July 2018